JP2020537517A5 - - Google Patents

Download PDF

Info

Publication number
JP2020537517A5
JP2020537517A5 JP2020519402A JP2020519402A JP2020537517A5 JP 2020537517 A5 JP2020537517 A5 JP 2020537517A5 JP 2020519402 A JP2020519402 A JP 2020519402A JP 2020519402 A JP2020519402 A JP 2020519402A JP 2020537517 A5 JP2020537517 A5 JP 2020537517A5
Authority
JP
Japan
Prior art keywords
epitope
nucleic acid
recombinant
specific polarization
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020519402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537517A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/054451 external-priority patent/WO2019071032A2/en
Publication of JP2020537517A publication Critical patent/JP2020537517A/ja
Publication of JP2020537517A5 publication Critical patent/JP2020537517A5/ja
Pending legal-status Critical Current

Links

JP2020519402A 2017-10-05 2018-10-04 Th1及びth2を刺激する多価抗原 Pending JP2020537517A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762568786P 2017-10-05 2017-10-05
US62/568,786 2017-10-05
PCT/US2018/054451 WO2019071032A2 (en) 2017-10-05 2018-10-04 MULTIVALENT ANTIGENS STIMULATING TH1 AND TH2

Publications (2)

Publication Number Publication Date
JP2020537517A JP2020537517A (ja) 2020-12-24
JP2020537517A5 true JP2020537517A5 (cg-RX-API-DMAC7.html) 2021-02-12

Family

ID=65994804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519402A Pending JP2020537517A (ja) 2017-10-05 2018-10-04 Th1及びth2を刺激する多価抗原

Country Status (8)

Country Link
US (1) US20200331976A1 (cg-RX-API-DMAC7.html)
EP (1) EP3692055A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020537517A (cg-RX-API-DMAC7.html)
KR (1) KR20200055136A (cg-RX-API-DMAC7.html)
CN (1) CN111417648A (cg-RX-API-DMAC7.html)
AU (1) AU2018346511A1 (cg-RX-API-DMAC7.html)
CA (1) CA3077424A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019071032A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110298124B (zh) * 2019-07-03 2020-10-27 江南大学 一种基于滤波的工业控制系统执行器参数估计方法
US11130787B2 (en) 2020-06-11 2021-09-28 MBF Therapeutics, Inc. Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100773109B1 (ko) * 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
DE60038622D1 (de) * 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
WO2001094419A2 (en) * 2000-06-07 2001-12-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method to induce the th1 immune response
ES2404689T3 (es) * 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
US9592284B2 (en) * 2004-04-28 2017-03-14 The Trustees Of The University Of Pennsylvania Immunization regimen with E4-deleted adenovirus prime and E1-deleted adenovirus boost
CA2760041A1 (en) * 2008-05-14 2009-11-19 Simons Haplomics Limited Methods and compositions for the treatment of cancer
US9795661B2 (en) * 2009-11-16 2017-10-24 The United States Of America As Represented By The Secretary Of The Navy TH1/TH2 polarizing vaccines
EA025280B1 (ru) * 2010-03-09 2016-12-30 Амир Максютов Полиэпитопные конструкции и способы их получения и применения
EP3027205A4 (en) * 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
CN108601820A (zh) * 2015-10-12 2018-09-28 南托米克斯有限责任公司 用于病毒癌症新表位的组合物和方法
JP2019513021A (ja) * 2016-03-24 2019-05-23 ナントセル,インコーポレイテッド ネオエピトープ提示のための配列の配置および配列

Similar Documents

Publication Publication Date Title
Xiao et al. CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
Draper et al. Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6
ES2836273T3 (es) Método para el tratamiento del cáncer
US12311018B2 (en) Targeted neoepitope vectors and methods therefor
AU2017233072B2 (en) Multimodal vector for dendritic cell infection
JP2017525336A5 (cg-RX-API-DMAC7.html)
JP2018509135A5 (cg-RX-API-DMAC7.html)
JP2019513021A (ja) ネオエピトープ提示のための配列の配置および配列
US20210369825A1 (en) Cd40 and cd40l combo in an adv vaccine vehicle
JP2018509163A5 (cg-RX-API-DMAC7.html)
JP2019508044A5 (cg-RX-API-DMAC7.html)
JP2010534463A5 (cg-RX-API-DMAC7.html)
JP2019524773A (ja) 樹状細胞のトランスフェクション及びその方法
JP2019509265A5 (cg-RX-API-DMAC7.html)
JP2013176373A (ja) T細胞レセプターβ鎖遺伝子及びα鎖遺伝子
US20210032371A1 (en) Enhanced Immunogenicity For GPI-anchored Antigens
Drakes et al. Lymph node–targeted vaccine boosting of TCR T-cell therapy enhances antitumor function and eradicates solid tumors
Bellone et al. Advances in dendritic cell-based therapeutic vaccines for cervical cancer
Shah et al. What do cancer-specific T cells ‘see’?
JP2022532271A5 (cg-RX-API-DMAC7.html)
FI3236985T4 (fi) Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa hepatosellulaarista karsinoomaa (hcc) ja muita syöpiä vastaan
US20200331976A1 (en) Multivalent Antigens Stimulating TH1 and TH2
Bhojnagarwala et al. synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy
Jung et al. 1421 Th1-specific epitope selection for an off-the-shelf type KRAS cancer vaccine: epitopes of non-mutated lesion
Shah et al. What do cancer-specific T cells ‘see’?